<DOC>
	<DOCNO>NCT02633046</DOCNO>
	<brief_summary>Multicenter , multiple dose study examine effect H.P . Acthar® Gel ( repository corticotropin injection ) adult subject idiopathic focal segmental glomerulosclerosis ( FSGS ) fail achieve remission , intolerant , 1 previous immunosuppressive therapy .</brief_summary>
	<brief_title>Treatment Proteinuria Due Treatment Resistant Treatment Intolerant Idiopathic FSGS</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion inclusion study Screening Visit/Visit 1 Baseline Visit/Visit 2 . 1 . Subjects must adequately inform understand nature risk study must able provide signature date ICF . 2 . Subjects must ≥ 18 year age Screening Visit/Visit 1 male female . 3 . Female subject must nonchildbearing potential ( history hysterectomy , bilateral oophorectomy , postmenopausal history menstrual flow 12 month prior Screening Visit/Visit 1 ) , childbearing potential must nonpregnant , nonlactating agree use effective contraception male partner throughout study participation 4 week end study participation . Acceptable form contraception include hormonal measure ( oral contraceptive pill , contraceptive patch , contraceptive ring , injection ) , intrauterine device , double barrier method ( condom plus diaphragm , condom diaphragm plus spermicidal gel foam ) , abstinence . 4 . Male subject female partner childbearing potential must surgically sterilize ( vasectomy ) agree use double barrier contraception ( condom plus diaphragm , condom diaphragm plus spermicidal gel foam ) remain abstinent throughout study participation 4 week end study participation . 5 . Subjects must history primary FSGS confirm renal biopsy ≤ 3 year prior Screening Visit/Visit 1 ; subject must history primary FSGS confirm biopsy perform 3 5 year prior Screening Visit/Visit 1 , investigator 's opinion , subject sign symptom clinical diagnosis could suggest change renal histology . Approval medical monitor ( MM ) require prior enrollment renal biopsy do 3 5 year prior Screening Visit/Visit 1 . 6 . Subjects must total urine protein creatinine ratio ( uPCR ) &gt; 3500 mg/g ( 396 mg/mmol ) Screening Visit/Visit 1 . 7 . Subjects must estimate glomerular filtration rate ( eGFR ) ≥ 30 mL/min/1.73 m2 Screening Visit/Visit 1 calculate 4variable modification diet renal disease ( MDRD ) study equation . 8 . Subjects must fail achieve sustain CR PR proteinuria determine investigator ≥ 1 prior immunosuppressive therapy , must intolerance ≥ 1 prior immunosuppressive therapy . 9 . Subjects must treat ACEi , ARB , DRI ≥ 4 week prior Screening Visit/Visit 1 stable maintenance dose ( ) ≥ 14 day prior Screening Visit/Visit 1 expect remain dose duration study document intolerance angiotensin convert enzyme inhibitor ( ACEi ) , angiotensin receptor blocker ( ARB ) , direct renin inhibitor ( DRI ) approval MM prior enrollment . Subjects take antihypertensive medication ( ) , must stable dose ≥ 4 week prior Screening Visit/Visit 1 . 10 . Subjects must mean systolic blood pressure ≤ 150 mm Hg diastolic blood pressure ≤ 90 mm Hg determine average ≥ 3 seat reading take least 5 minute apart Screening Visit/Visit 1 Baseline Visit/Visit 2 . 11 . Subjects must able communicate effectively study personnel . 12 . Subjects must able willing follow protocol requirement study restriction . 13 . Subjects must able willing return study visit . Exclusion Criteria Subjects ineligible study participation meet follow criterion Screening Visit/Visit 1 Baseline Visit/Visit 2 . 1 . Subject vulnerable population , define US CFR Title 45 , Part 46 , Section 46.111 ( b ) local national regulation , include limited , employee ( temporary , parttime , full time , etc ) family member research staff conduct study , sponsor , clinical research organization , IRB/IEC . 2 . Subject unwilling receive , intolerant , subcutaneous injection . 3 . Subject history use ACTH preparation treatment nephrotic syndrome ( include limit Acthar Synacthen® ) . 4 . Subject history sensitivity ACTH preparation ( include limit Acthar Synacthen ) . 5 . Subject history sensitivity porcine protein product . 6 . Subject body mass index ( BMI ) &gt; 45 kg/m2 Screening Visit/Visit 1 . 7 . Subject secondary FSGS , include limited , obesity , know genetic cause , reduce kidney mass , Human Immunodeficiency Virus ( HIV ) , intravenous heroin abuse , sickle cell anemia . 8 . Subject renal biopsy demonstrate &gt; 50 % global glomerular senescence , &gt; 50 % cortical interstitial fibrosis , collapse FSGS . 9 . Subject know contraindication ( ) Acthar ( Mallinckrodt ARD , 2015 ) include , limited : Any known history scleroderma , osteoporosis , ocular herpes simplex . Any current uncontrolled hypertension , primary adrenocortical insufficiency , adrenal cortical hyperfunction . Any current congestive heart failure ( defined New York Heart Association Functional Class III IV ) . Peptic ulcer ( within 6 month prior Screening Visit/Visit 1 ) . Recent major surgery ( within 6 month prior Screening Visit/Visit 1 , renal biopsy consider exclusionary surgical procedure ) . 10 . Subject history chronic active hepatitis ; active chronic hepatitis B ; acute chronic hepatitis C. 11 . Subject history tuberculosis ( TB ) infection , signs/symptoms TB , close contact individual active TB infection . 12 . Subject clinically significant infection require intravenous administration antibiotic hospitalization 4 week prior Screening Visit/Visit 1 . 13 . Subject know immune compromise status , include limited , individual undergo organ transplantation know positive HIV . 14 . Subject Type 1 Type 2 diabetes mellitus ( prior diagnosis gestational diabetes mellitus exclusionary ) . 15 . Subject follow 12 week prior Screening Visit 1/Visit 1 : unstable angina confirm cardiologist , myocardial infarction , coronary artery bypass graft , percutaneous transluminal coronary angioplasty , transient ischemic attack cerebrovascular disease , unstable cardiac arrhythmia , resuscitate sudden cardiac death . 16 . Subject solid tumor malignancy currently diagnose undergoing therapy , receive therapy solid tumor malignancy 5 year prior Screening Visit/Visit 1 , exception treat cured basal cell carcinoma , treat cure squamous cell carcinoma skin , treat cure carcinoma situ cervix . 17 . Subject diagnosis , undergo therapy , receive therapy hematologic malignancy 5 year prior Screening Visit/Visit 1 . 18 . Subject treatment prohibit medication within specify timeframe prior Screening Visit/Visit 1 . 19 . Subject treatment prohibit medication within specify timeframe prior Baseline Visit/Visit 2 . 20 . Subject current recent ( within 6 month Screening Visit/Visit 1 ) drug alcohol abuse define Diagnostic Statistical Manual Mental Disorders , Fifth Edition , Diagnostic Criteria Drug Alcohol Abuse ( American Psychiatric Association , 2013 ) . 21 . Subject follow laboratory abnormality Screening Visit/Visit1 : Hemoglobin ≤ 8.0 g/dL . Platelets ≤ 50,000 cells/µL . Absolute neutrophil count ( ANC ) ≤ 1000 cells/µL . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin &gt; 2 time upper limit normal ( ULN ) . Glycosylated hemoglobin ( HbA1c ) &gt; 7.5 % . Positive Hepatitis B surface antigen ( HBsAg ) Hepatitis B core antibody ( HBcAb ) . Positive Hepatitis C virus antibody ( HCV ) HCV polymerase chain reaction ( PCR ) ≥ 25 IU/mL ( HCV PCR automatically analyze HCV positive ) . Positive indeterminate interferon gamma release assay ( IGRA ) . 22 . Subject clinically significant disease , disorder laboratory abnormality . 23 . Subjects fail achieve remission 2 prior immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>FSGS</keyword>
	<keyword>primary FSGS</keyword>
	<keyword>idiopathic FSGS</keyword>
</DOC>